Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Cipla
Chubb
Citi
Express Scripts
Fuji
Julphar
QuintilesIMS
Argus Health
Daiichi Sankyo

Generated: October 22, 2017

DrugPatentWatch Database Preview

HYZAAR Drug Profile

« Back to Dashboard

Which patents cover Hyzaar, and what generic Hyzaar alternatives are available?

Hyzaar is a drug marketed by Merck Sharp Dohme and is included in one NDA.

The generic ingredient in HYZAAR is hydrochlorothiazide; losartan potassium. There are thirty-one drug master file entries for this compound. Forty-four suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; losartan potassium profile page.

Summary for Tradename: HYZAAR

US Patents:0
Applicants:1
NDAs:1
Suppliers / Packagers: see list7
Bulk Api Vendors: see list122
Clinical Trials: see list16
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:HYZAAR at DailyMed

Pharmacology for Tradename: HYZAAR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck Sharp Dohme
HYZAAR
hydrochlorothiazide; losartan potassium
TABLET;ORAL020387-001Apr 28, 1995ABRXYesNo► Subscribe► Subscribe► Subscribe
Merck Sharp Dohme
HYZAAR
hydrochlorothiazide; losartan potassium
TABLET;ORAL020387-003Oct 20, 2005ABRXYesNo► Subscribe► Subscribe► Subscribe
Merck Sharp Dohme
HYZAAR
hydrochlorothiazide; losartan potassium
TABLET;ORAL020387-002Nov 10, 1998ABRXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: HYZAAR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck Sharp Dohme
HYZAAR
hydrochlorothiazide; losartan potassium
TABLET;ORAL020387-003Oct 20, 2005► Subscribe► Subscribe
Merck Sharp Dohme
HYZAAR
hydrochlorothiazide; losartan potassium
TABLET;ORAL020387-001Apr 28, 1995► Subscribe► Subscribe
Merck Sharp Dohme
HYZAAR
hydrochlorothiazide; losartan potassium
TABLET;ORAL020387-002Nov 10, 1998► Subscribe► Subscribe
Merck Sharp Dohme
HYZAAR
hydrochlorothiazide; losartan potassium
TABLET;ORAL020387-002Nov 10, 1998► Subscribe► Subscribe
Merck Sharp Dohme
HYZAAR
hydrochlorothiazide; losartan potassium
TABLET;ORAL020387-001Apr 28, 1995► Subscribe► Subscribe
Merck Sharp Dohme
HYZAAR
hydrochlorothiazide; losartan potassium
TABLET;ORAL020387-001Apr 28, 1995► Subscribe► Subscribe
Merck Sharp Dohme
HYZAAR
hydrochlorothiazide; losartan potassium
TABLET;ORAL020387-003Oct 20, 2005► Subscribe► Subscribe
Merck Sharp Dohme
HYZAAR
hydrochlorothiazide; losartan potassium
TABLET;ORAL020387-001Apr 28, 1995► Subscribe► Subscribe
Merck Sharp Dohme
HYZAAR
hydrochlorothiazide; losartan potassium
TABLET;ORAL020387-002Nov 10, 1998► Subscribe► Subscribe
Merck Sharp Dohme
HYZAAR
hydrochlorothiazide; losartan potassium
TABLET;ORAL020387-002Nov 10, 1998► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for HYZAAR

Drugname Dosage Strength RLD Submissiondate
losartan potassium and hydrochlorothiazideTablets100 mg/12.5 mLHyzaar4/4/2006
losartan potassium and hydrochlorothiazideTablets50 mg/12.5 mg and 100 mg/25 mgHyzaar5/24/2004
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Johnson and Johnson
AstraZeneca
Cipla
Deloitte
Chubb
Teva
Julphar
Baxter
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot